Seoul, South Korea & Zug, Switzerland – [Current Date, e.g., November 15, 2024] – Samsung Biologics, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has announced its intention to acquire PolyPeptide Group AG, a prominent global CDMO specializing in peptide-based active pharmaceutical ingredients (APIs), through an all-cash public tender offer. The acquisition, valued at approximately SFr1.46 billion ($1.81 billion), marks a significant strategic expansion for Samsung Biologics, positioning the company to capitalize on the rapidly growing demand for peptide therapeutics, particularly in high-growth areas like GLP-1 agonists.
n
The proposed offer stands at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. This valuation represents a substantial premium of 40% to PolyPeptide’s last undisturbed share price as of April 10, 2026, and approximately an 11.6% premium to its 60-day volume-weighted average price. The transaction is anticipated to conclude towards the end of 2026, contingent upon meeting a minimum acceptance threshold of nearly 67% of PolyPeptide’s outstanding shares, obtaining necessary regulatory approvals, and satisfying other customary conditions under Swiss takeover law.
n
This move underscores Samsung Biologics’ ambition to diversify its service portfolio beyond its established leadership in antibody and antibody-drug conjugate (ADC) manufacturing. By integrating PolyPeptide’s specialized capabilities, Samsung Biologics aims to become a more comprehensive, end-to-end CDMO partner, addressing the evolving needs of the global pharmaceutical and biotechnology industries.
n
The Strategic Rationale: A Deeper Dive into Modality Expansion and Market Opportunity
n
Samsung Biologics’ decision to acquire PolyPeptide Group is a meticulously calculated strategic move aimed at capturing a larger share of the burgeoning peptide therapeutics market. While Samsung Biologics has cemented its reputation as a powerhouse in large molecule biologics manufacturing, particularly monoclonal antibodies and, more recently, antibody-drug conjugates (ADCs), the acquisition of PolyPeptide represents a decisive step into the realm of small to medium-sized molecules, specifically peptides.
n
Expanding Beyond Traditional Biologics: The global pharmaceutical landscape is witnessing a diversification of therapeutic modalities. While biologics continue their rapid growth trajectory, peptide therapeutics are experiencing a renaissance, driven by advancements in synthesis technology, improved drug delivery systems, and a deeper understanding of their biological mechanisms. Peptides offer unique advantages, including high specificity, lower immunogenicity compared to larger proteins, and relatively shorter development cycles. By venturing into peptides, Samsung Biologics mitigates reliance on a single type of modality and broadens its appeal to a wider client base.
n
Capitalizing on the GLP-1 Boom: A key driver behind this acquisition is undoubtedly the explosive growth in the market for glucagon-like peptide-1 (GLP-1) receptor agonists. These peptides have revolutionized the treatment of Type 2 diabetes and, more recently, obesity, with several blockbuster drugs already on the market and a robust pipeline of new candidates. The demand for manufacturing capacity for GLP-1 APIs is skyrocketing, and PolyPeptide, with its extensive experience and established infrastructure in peptide synthesis, is perfectly positioned to meet this demand. Samsung Biologics’ CEO, John Rim, explicitly highlighted "modality expansion into peptides including GLP-1" as a core component of the acquisition’s rationale, signaling a clear intent to become a dominant player in this high-growth segment. This strategic foresight aligns Samsung Biologics with one of the most significant therapeutic trends of the decade.
n
Geographic Reach and Proximity: PolyPeptide’s global operational footprint is another crucial asset that attracted Samsung Biologics. With facilities spanning Belgium, France, India, Sweden, and the United States, alongside a corporate office in Switzerland and an Innovation Centre in France, PolyPeptide offers a geographically diversified manufacturing and R&D network. This expansion significantly boosts Samsung Biologics’ "geographic reach and proximity further within the US, Europe, and India."
n
- n
- Europe: PolyPeptide’s European sites provide critical access to key pharmaceutical markets and a highly skilled workforce, aligning with European regulatory standards.
- United States: A strong presence in the U.S. is vital for serving the world’s largest pharmaceutical market, enabling closer collaboration with U.S.-based biotech and pharma companies.
- India: PolyPeptide’s Indian operations offer strategic advantages in terms of cost-efficiency and access to a rapidly growing pharmaceutical market and talent pool, crucial for scalability and global supply chain resilience.
n
n
n
n
This geographical diversification not only enhances service delivery but also strengthens supply chain robustness, a critical consideration in an increasingly complex and globalized pharmaceutical industry.
n
Chronology of the Deal and Shareholder Commitment
n
The journey towards this landmark acquisition began with a strategic assessment by Samsung Biologics to identify growth opportunities in complementary therapeutic areas. The offer price of SFr44.31 per share was meticulously determined, reflecting a substantial premium for PolyPeptide’s shareholders. The 40% premium over the undisturbed share price of April 10, 2026, signals Samsung Biologics’ strong conviction in PolyPeptide’s value and future potential, as well as its commitment to securing the acquisition.
n
A pivotal development in the tender offer is the unanimous recommendation by PolyPeptide’s board of directors, acting through its independent and non-conflicted members, for shareholders to accept the tender offer. This endorsement is crucial for garnering widespread shareholder support, as it signals the board’s belief that the offer represents a fair and attractive value for the company.
n
Furthermore, the offer has received a significant boost from PolyPeptide’s largest shareholder, who holds approximately 55.65% of the outstanding shares (excluding treasury shares). This major shareholder has provided an irrevocable undertaking to tender its shares into the offer. This commitment is a game-changer, as it substantially de-risks the transaction by virtually guaranteeing that the minimum acceptance threshold of nearly 67% will be met. This strong pre-commitment from the largest shareholder provides a high degree of certainty for Samsung Biologics, streamlining the acquisition process and reducing potential uncertainties typically associated with public tender offers.
n
The anticipated completion towards the end of 2026 allows for ample time to navigate the necessary regulatory approval processes across various jurisdictions where both companies operate or have significant market presence. These approvals, particularly antitrust clearances, are standard for transactions of this magnitude and ensure fair competition in the market.
n
PolyPeptide Group: A Legacy of Peptide Innovation
n
PolyPeptide Group is not merely a manufacturing facility; it is a global leader with a rich history and deep expertise in the complex field of peptide synthesis. The company specializes in peptide-based active pharmaceutical ingredients (APIs), which are the biologically active components of peptide drugs. The quality and purity of these APIs are paramount to the safety and efficacy of the final therapeutic product.
n
Core Expertise: PolyPeptide’s core competence lies in the custom synthesis of therapeutic peptides, ranging from early-stage clinical development to large-scale commercial manufacturing. Their expertise encompasses various peptide synthesis technologies, including solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS), as well as hybrid approaches. This technological versatility allows them to tackle a broad spectrum of complex peptide molecules, catering to diverse client needs.
n
Impressive Track Record: Over its history, PolyPeptide has produced more than 1,000 therapeutic peptides, a testament to its extensive experience, technical capabilities, and robust quality systems. This vast portfolio includes peptides for various therapeutic areas, such as metabolic disorders (including GLP-1s), oncology, central nervous system disorders, infectious diseases, and rare diseases. This proven track record makes PolyPeptide an invaluable asset, bringing not only capacity but also critical intellectual capital and a deep understanding of the regulatory landscape for peptide therapeutics.
n
Global Footprint and Innovation: PolyPeptide’s strategically located facilities are key to its global reach and operational excellence:
n
- n
- Belgium, France, Sweden, USA, India: These manufacturing sites are equipped with state-of-the-art technology and operate under strict Good Manufacturing Practice (GMP) standards, ensuring the highest quality and regulatory compliance for API production.
- Innovation Centre in France: This dedicated R&D facility plays a crucial role in developing novel peptide synthesis routes, improving manufacturing efficiency, and supporting clients in their early-stage peptide drug development. This focus on innovation ensures that PolyPeptide remains at the forefront of peptide technology.
- Corporate Office in Switzerland: Located in Zug, Switzerland, a hub for pharmaceutical and biotech companies, provides a strategic base for global management and client relations.
n
n
n
n
This integrated network of manufacturing, R&D, and corporate functions positions PolyPeptide as a truly global and comprehensive peptide CDMO, perfectly complementing Samsung Biologics’ existing strengths.
The CDMO Landscape and Market Implications
The acquisition of PolyPeptide by Samsung Biologics is not just a transaction between two companies; it is a significant event that will reverberate across the global Contract Development and Manufacturing Organization (CDMO) sector.
Growing Demand for Integrated Services: The pharmaceutical industry is increasingly relying on CDMOs for specialized expertise, cost efficiencies, and accelerated timelines. There is a strong trend towards "one-stop shop" CDMOs that can offer integrated services across various modalities and stages of drug development and manufacturing. This acquisition enables Samsung Biologics to offer a broader suite of services, from DNA to drug product for biologics, and now encompassing peptide API manufacturing. This integrated approach can reduce complexity for clients, streamline supply chains, and potentially accelerate time to market for new drugs.
Peptide Market Growth: The global peptide therapeutics market is projected to grow substantially in the coming years, driven by the success of existing drugs and a robust pipeline of new candidates. Factors contributing to this growth include:
- Technological Advancements: Improved peptide synthesis techniques, purification methods, and analytical tools have made peptide drug development more efficient and cost-effective.
- Expanding Therapeutic Applications: Peptides are being explored for a wider range of indications, including oncology, cardiovascular diseases, anti-infectives, and rare diseases, in addition to metabolic disorders.
- Biotech Innovation: A surge in biotech startups focusing on novel peptide platforms is fueling demand for specialized CDMO services.
By acquiring PolyPeptide, Samsung Biologics is making a decisive move to secure a leading position in this high-growth segment, further solidifying its standing as a diversified CDMO leader.
Competitive Landscape: The CDMO market is highly competitive, with players vying for market share through capacity expansion, technological innovation, and strategic acquisitions. Major competitors include Lonza, Catalent (currently undergoing acquisition by Novo Holdings), WuXi Biologics, and others. This acquisition allows Samsung Biologics to differentiate itself by offering a unique combination of large molecule and specialized peptide manufacturing capabilities under one roof, potentially attracting new clients who seek a comprehensive partner. It also strengthens its position against competitors who may specialize in only one modality.
Official Responses and Future Outlook
John Rim, CEO and Chairman of the Board of Directors at Samsung Biologics, articulated the strategic significance of the acquisition, stating: "This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India. We highly value PolyPeptide’s world-class employees, industry-leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come." Rim’s statement emphasizes the comprehensive nature of the deal, highlighting diversification, global expansion, and the long-term vision of becoming an indispensable partner for pharmaceutical innovators.
Upon successful completion of the tender offer, Samsung Biologics plans to acquire all remaining shares of PolyPeptide and subsequently delist the company from the SIX Swiss Exchange. This move indicates a full integration strategy, aiming to align PolyPeptide’s operations seamlessly within the broader Samsung Biologics framework. Delisting is a common practice in such acquisitions, providing the acquiring company with full control and flexibility to execute its integration plans without the complexities of public market reporting for the acquired entity.
Potential Synergies and Integration: The integration process will be critical. Samsung Biologics will likely focus on leveraging PolyPeptide’s deep expertise in peptide chemistry and manufacturing, while PolyPeptide will benefit from Samsung Biologics’ robust quality systems, global client network, and financial strength. Potential synergies include:
- Cross-selling opportunities: Offering peptide manufacturing services to existing Samsung Biologics clients and biologics manufacturing services to PolyPeptide’s client base.
- Operational efficiencies: Optimizing manufacturing processes, supply chains, and procurement across the combined entity.
- Enhanced R&D: Combining innovation efforts to develop next-generation peptide synthesis technologies or novel peptide-based drug candidates.
- Talent pool: Integrating highly skilled scientific and manufacturing talent, fostering a culture of shared innovation and excellence.
However, integrating two companies with different corporate cultures, operational procedures, and geographical footprints also presents challenges. Samsung Biologics will need to carefully manage this transition to ensure business continuity, retain key talent, and maintain the high quality standards for which both companies are known.
Advisory Teams and Due Diligence
Transactions of this magnitude require extensive financial, legal, and accounting expertise. For Samsung Biologics, JP Morgan is serving as its exclusive financial adviser, guiding the company through the valuation, structuring, and negotiation aspects of the tender offer. Ernst & Young Han Young is providing crucial accounting and tax advice, ensuring compliance and optimizing the financial implications of the deal. Legal counsel is being provided by O’Melveny & Myers and Schellenberg Wittmer, navigating the complexities of corporate law, M&A regulations, and Swiss takeover law. The involvement of these reputable advisory firms underscores the meticulous due diligence and professional execution underpinning this strategic acquisition.
Broader Context: Samsung Biologics’ Continuous Growth Trajectory
This acquisition is consistent with Samsung Biologics’ overarching strategy of aggressive expansion and diversification. The company has been consistently investing in new manufacturing plants (its ‘Bio Campus’ strategy), expanding its capacity to meet the surging global demand for biologics manufacturing.
Earlier this year, for instance, Samsung Biologics partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) in an outbreak-ready vaccine manufacturing initiative. This collaboration aims to enhance global vaccine production preparedness for pandemic threats and future epidemics, further demonstrating Samsung Biologics’ commitment to global health and its willingness to expand its capabilities into critical new areas. This broader strategic context highlights a company that is not just growing but also strategically positioning itself as a versatile and resilient partner in the global pharmaceutical ecosystem.
Conclusion
The proposed acquisition of PolyPeptide Group by Samsung Biologics is a landmark deal that signifies a pivotal moment for both companies and the broader pharmaceutical CDMO industry. For Samsung Biologics, it represents a bold leap into the rapidly expanding peptide therapeutics market, particularly the high-demand GLP-1 segment, significantly diversifying its service offerings and strengthening its position as an integrated, global CDMO. For PolyPeptide, it offers the opportunity to integrate with a global powerhouse, benefiting from Samsung Biologics’ vast resources, client network, and ambitious growth vision.
As the pharmaceutical industry continues to innovate with diverse therapeutic modalities, the ability to offer comprehensive, high-quality manufacturing solutions across various molecule types will be a key differentiator. This acquisition positions Samsung Biologics to meet this evolving demand, ultimately contributing to the accelerated development and broader accessibility of life-changing medicines for patients worldwide. The coming years will reveal the full extent of the synergies and strategic advantages unlocked by this ambitious union, but the message is clear: Samsung Biologics is building a formidable, future-ready CDMO enterprise.
